iData Insights

Progen Pharmaceuticals Limited - Product Pipeline Review – 2015 Is Released

Press Release   •   Feb 08, 2016 19:05 IST

This report provides comprehensive information on the current therapeutic developmental pipeline of Progen Pharmaceuticals Limiteds, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope

The report provides brief overview of Progen Pharmaceuticals Limited including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Progen Pharmaceuticals Limiteds human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the products developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Progen Pharmaceuticals Limiteds pipeline products Reasons to buy - Evaluate Progen Pharmaceuticals Limiteds strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Progen Pharmaceuticals Limited in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Progen Pharmaceuticals Limited s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Progen Pharmaceuticals Limited and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Progen Pharmaceuticals Limited - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Progen Pharmaceuticals Limited and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues

Browse Complete Report with TOC http://www.idatainsights.com/reports-landing-page.php?id=179148/progen-pharmaceuticals-limited-product-pipeline-review-2015

To Get Sample Copy of Report visit http://www.idatainsights.com/reports-landing-page.php?id=179148/progen-pharmaceuticals-limited-product-pipeline-review-2015

Table of Contents

Table of Contents 2

List of Tables 3

List of Figures 3

Progen Pharmaceuticals Limited Snapshot 4

Progen Pharmaceuticals Limited Overview 4

Key Information 4

Key Facts 4

Progen Pharmaceuticals Limited - Research and Development Overview 5

Key Therapeutic Areas 5

Progen Pharmaceuticals Limited - Pipeline Review 7

Pipeline Products by Stage of Development 7

Pipeline Products - Monotherapy 8

Progen Pharmaceuticals Limited - Pipeline Products Glance 9

Progen Pharmaceuticals Limited - Late Stage Pipeline Products 9

Phase III Products/Combination Treatment Modalities 9

Progen Pharmaceuticals Limited - Clinical Stage Pipeline Products 10

Phase I Products/Combination Treatment Modalities 10

Progen Pharmaceuticals Limited - Early Stage Pipeline Products 11

Preclinical Products/Combination Treatment Modalities 11

Discovery Products/Combination Treatment Modalities 12

Progen Pharmaceuticals Limited - Drug Profiles 13

muparfostat sodium 13

Product Description 13

Mechanism of Action 13

R&D Progress 13

PG-545 16

Product Description 16

Mechanism of Action 16

R&D Progress 16

Small Molecules to Target Heparanase for Oncology, Immunology and Diabetes 18

Product Description 18

Mechanism of Action 18

R&D Progress 18

Progen Pharmaceuticals Limited - Pipeline Analysis 19

Progen Pharmaceuticals Limited - Pipeline Products by Target 19

Progen Pharmaceuticals Limited - Pipeline Products by Route of Administration 20

Progen Pharmaceuticals Limited - Pipeline Products by Molecule Type 21

Progen Pharmaceuticals Limited - Pipeline Products by Mechanism of Action 22

Progen Pharmaceuticals Limited - Recent Pipeline Updates 23

Progen Pharmaceuticals Limited - Dormant Projects 25

Progen Pharmaceuticals Limited - Discontinued Pipeline Products 26

Discontinued Pipeline Product Profiles 26

PG-562 26

Progen Pharmaceuticals Limited - Company Statement 27

Progen Pharmaceuticals Limited - Locations And Subsidiaries 29

Head Office 29

Other Locations & Subsidiaries 29

Appendix 30

Methodology 30

Coverage 30

Secondary Research 30

Primary Research 30

Expert Panel Validation 30

Contact Us 30

Disclaimer 31" width="80" height="40" />Table of Contents

Table of Contents 2

List of Tables 3

List of Figures 3

Progen Pharmaceuticals Limited Snapshot 4

Progen Pharmaceuticals Limited Overview 4

Key Information 4

Key Facts 4

Progen Pharmaceuticals Limited - Research and Development Overview 5

Key Therapeutic Areas 5

Progen Pharmaceuticals Limited - Pipeline Review 7

Pipeline Products by Stage of Development 7

Pipeline Products - Monotherapy 8

Progen Pharmaceuticals Limited - Pipeline Products Glance 9

Progen Pharmaceuticals Limited - Late Stage Pipeline Products 9

Phase III Products/Combination Treatment Modalities 9

Progen Pharmaceuticals Limited - Clinical Stage Pipeline Products 10

Phase I Products/Combination Treatment Modalities 10

Progen Pharmaceuticals Limited - Early Stage Pipeline Products 11

Preclinical Products/Combination Treatment Modalities 11

Discovery Products/Combination Treatment Modalities 12

Progen Pharmaceuticals Limited - Drug Profiles 13

muparfostat sodium 13

Product Description 13

Mechanism of Action 13

R&D Progress 13

PG-545 16

Product Description 16

Mechanism of Action 16

R&D Progress 16

Small Molecules to Target Heparanase for Oncology, Immunology and Diabetes 18

Product Description 18

Mechanism of Action 18

R&D Progress 18

Progen Pharmaceuticals Limited - Pipeline Analysis 19

Progen Pharmaceuticals Limited - Pipeline Products by Target 19

Progen Pharmaceuticals Limited - Pipeline Products by Route of Administration 20

Progen Pharmaceuticals Limited - Pipeline Products by Molecule Type 21

Progen Pharmaceuticals Limited - Pipeline Products by Mechanism of Action 22

Progen Pharmaceuticals Limited - Recent Pipeline Updates 23

Progen Pharmaceuticals Limited - Dormant Projects 25

Progen Pharmaceuticals Limited - Discontinued Pipeline Products 26

Discontinued Pipeline Product Profiles 26

PG-562 26

Progen Pharmaceuticals Limited - Company Statement 27

Progen Pharmaceuticals Limited - Locations And Subsidiaries 29

Head Office 29

Other Locations & Subsidiaries 29

Appendix 30

Methodology 30

Coverage 30

Secondary Research 30

Primary Research 30

Expert Panel Validation 30

Contact Us 30

Disclaimer 31

Read More http://www.idatainsights.com/reports-landing-page.php?id=179148/progen-pharmaceuticals-limited-product-pipeline-review-2015

About Us:

iData Insights which operates under Precision Research and Consulting Private Limited is a leading market research information aggregator and marketing research consulting firm. We conduct both primary and secondary research. Our work does not end with research it is also involved in distributing reports for different companies . We provide actionable recommendations and provide our expertise for business success today and tomorrow. It is our goal to be a partner to our clients in the exploration and discovery, and then be their guide in the implementation of changes that will make a difference to their bottom line.

ContactUs:
iData Insights

Tel: 1-866-237-2965

Web: http://www.idatainsights.com
Email: info@idatainsights.com

AboutiData Insights

We work around the clock until our clients are completely satisfied with their promised results. It is our mission to provide timely services coupled with acute client care to create a long-lasting relationship with you. We deliver on our promise to provide results that are essential to the success of your company. We believe that by doing so, we will earn the trust of our clients for future project.